Evidence map›Paper›PMID 30528374›Full record

ReviewNeuroscience and biobehavioral reviews2019

Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Sandra D Comer, Catherine M Cahill

Abstract readReview
In one paragraph

Review in Neuroscience and biobehavioral reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Acute fentanyl induces opposing directions of changes in tonic and phasic dopamine release patterns and impairs Pavlovian task performance.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  9. Article
  10. Dose- and time-dependent physiological effects of fentanyl in adult goats.Journal of applied physiology (Bethesda, Md. : 1985) · 2026
    Article
  11. Assessment of Test Strips for Detection of Fentanyl in Powders.Prevention science : the official journal of the Society for Prevention Research · 2026
    Article
  12. Article
  13. Article
  14. Carfentanil Depresses Inspiratory Motor Drive.Journal of substance abuse and alcoholism · 2026
    Article
  15. Article
  16. Article
  17. Early axonal injury in fentanyl intoxication.Acta neuropathologica communications · 2026
    Article
  18. Antinociceptive Effect and Hyperalgesia of Fentanyl and Its Analogues.International journal of molecular sciences · 2026
    Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sandra D ComerNew York State Psychiatric Institute and Columbia University, New York, NY, 10027, United States. Electronic address: sdc10@cumc.columbia.edu.
Catherine M CahillSemel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, 90095, United States.

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, XIANGDONG WILLIAM · 1987 to 2021
$30.7M
Training and Education CoreU54DA037842 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI LEVIN, FRANCES RUDNICK · 2014 to 2018
$14.3M
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin UsersR01DA035207 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D · 2014 to 2018
$2.7M
Dissecting circuits mediating pain-induced alterations in motivated behaviorR01DA041781 · NIDA · WASHINGTON UNIVERSITY · PI MORON-CONCEPCION, JOSE A · 2017 to 2021
$2.3M
Medication Development for Opioid and Alcohol Abuse: Laboratory Studies in HumansR01DA039169 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D · 2017 to 2018
$1.3M
NIDA NIH HHS P50 DA005010NIDA NIH HHS R01 DA035207NIDA NIH HHS R01 DA039169NIDA NIH HHS R01 DA041781NIDA NIH HHS U54 DA037842
6 · The paper itself

Abstract

Opioid overdoses, many of which are attributed to use of illicit fentanyl, are currently one of the leading causes of death in the U.S. Although fentanyl has been used safely for decades in clinical settings, the widespread use of illicit fentanyl is a recent phenomenon. Starting in 2013, illicitly manufactured fentanyl and its analogs began to appear on the streets. These substances were added to or sold as heroin, often unbeknownst to the user. Because fentanyl is so potent, only small amounts are needed to produce pharmacological effects, but the margin between safe and toxic doses is narrow. Surprisingly little is known about the exact signaling mechanisms underlying fentanyl-related respiratory depression or the effectiveness of naloxone in reversing this effect. Similarly, little is known about the ability of treatment medications such as buprenorphine, methadone, or naltrexone to reduce illicit fentanyl use. The present article reviews the receptor, preclinical and clinical pharmacology of fentanyl, and how its pharmacology may predict the effectiveness of currently approved medications for treating illicit fentanyl use.

Indexed as

Analgesics, OpioidFentanylHumansOpiate Substitution TreatmentOpioid-Related DisordersReceptors, Opioid, muAnalgesics, OpioidFentanylReceptors, Opioid, muAbuseBeta-arrestinBuprenorphineEfficacyFentanylHeroinIllicitMethadoneNaltrexonePainPharmacologySelf-administrationSubjective effectsTreatment

Identifiers

PMID30528374
PMCPMC7233332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.